Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva Hellström Lindberg

Showing results (1-10 of 191) with videos related to

Pageof 20
Sort By:
Current Hematology Reports|August 7, 2003
Approach to anemia associated with myelodysplastic syndromesEva Hellström-Lindberg
Current Drug Targets|September 24, 2005
Strategies for biology- and molecular-based treatment of myelodysplastic syndromesEva Hellström Lindberg
Blood Reviews|February 23, 2010
Significance of JAK2 and TET2 mutations in myelodysplastic syndromesEva Hellström-Lindberg
Leukemia & Lymphoma|June 25, 2010
Erythropoiesis-stimulating agents in myelodysplastic syndromesEva Hellström-Lindberg
Hematology. American Society of Hematology. Education Program|December 17, 2008
Myelodysplastic syndromes: an historical perspectiveEva Hellström-Lindberg
Hematology. American Society of Hematology. Education Program|November 24, 2005
Update on supportive care and new therapies: immunomodulatory drugs, growth factors and epigenetic-acting agentsEva Hellström-Lindberg
International Journal of Hematology|April 10, 2002
Sixth International Symposium on Myelodysplastic Syndromes, Stockholm, June 14-17, 2001Eva Hellström-Lindberg
Hematology. American Society of Hematology. Education Program|December 17, 2008
The role of JAK2 mutations in RARS and other MDSEva Hellström-Lindberg, Mario Cazzola
Seminars in Hematology|January 9, 2008
Supportive care and use of hematopoietic growth factors in myelodysplastic syndromesEva Hellström-Lindberg, Luca Malcovati
Experimental Cell Research|March 10, 2010
New clues to the molecular pathogenesis of myelodysplastic syndromesMartin Jädersten, Eva Hellström-Lindberg
Pageof 20

Showing results (1-10 of 191) with videos related to

Sort By:
Pageof 20
Current Hematology Reports|August 7, 2003
Approach to anemia associated with myelodysplastic syndromesEva Hellström-Lindberg
Current Drug Targets|September 24, 2005
Strategies for biology- and molecular-based treatment of myelodysplastic syndromesEva Hellström Lindberg
Blood Reviews|February 23, 2010
Significance of JAK2 and TET2 mutations in myelodysplastic syndromesEva Hellström-Lindberg
Leukemia & Lymphoma|June 25, 2010
Erythropoiesis-stimulating agents in myelodysplastic syndromesEva Hellström-Lindberg
Hematology. American Society of Hematology. Education Program|December 17, 2008
Myelodysplastic syndromes: an historical perspectiveEva Hellström-Lindberg
Hematology. American Society of Hematology. Education Program|November 24, 2005
Update on supportive care and new therapies: immunomodulatory drugs, growth factors and epigenetic-acting agentsEva Hellström-Lindberg
International Journal of Hematology|April 10, 2002
Sixth International Symposium on Myelodysplastic Syndromes, Stockholm, June 14-17, 2001Eva Hellström-Lindberg
Hematology. American Society of Hematology. Education Program|December 17, 2008
The role of JAK2 mutations in RARS and other MDSEva Hellström-Lindberg, Mario Cazzola
Seminars in Hematology|January 9, 2008
Supportive care and use of hematopoietic growth factors in myelodysplastic syndromesEva Hellström-Lindberg, Luca Malcovati
Experimental Cell Research|March 10, 2010
New clues to the molecular pathogenesis of myelodysplastic syndromesMartin Jädersten, Eva Hellström-Lindberg
Pageof 20